載入中
NASDAQHealthcareBiotechnology
最新資料
US$6.73
+US$0.94 · +16.23%
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
前收盤價
US$6.73
+US$0.94 · +16.23%
盤中時間採用ET。市場資料可能有所延遲。
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
日內區間
目前US$6.73
52週區間
目前US$6.73
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
60
合理估值
情緒
49
多空交錯
風險
66
高風險
動能
19
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
日內區間
目前US$6.73
52週區間
目前US$6.73
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 59.68萬 USD | 51.04萬 USD | 35.01萬 USD | — | — |
| 銷貨成本 | 63.9萬 USD | 35.5萬 USD | 19.67萬 USD | — | — |
| 毛利 | −4.21萬 USD | 15.54萬 USD | 15.34萬 USD | — | — |
| 研究與開發 | 160.21萬 USD | 49.14萬 USD | — | — | — |
| 銷售、一般及管理費用 | 362.75萬 USD | 112.64萬 USD | 16.06萬 USD | 232.32萬 USD | 172.24萬 USD |
| 營業費用 | 522.96萬 USD | 161.73萬 USD | 16.33萬 USD | 232.32萬 USD | 172.24萬 USD |
| 利息收入 | 8.02萬 USD | 1.18萬 USD | 290 USD | 813 USD | 764 USD |
| 利息支出 | — | 772 USD | 2144 USD | — | — |
| 折舊和攤銷 | 20.96萬 USD | 10.47萬 USD | 2452 USD | — | — |
| 營業利益 | −527.17萬 USD | −146.19萬 USD | −9847 USD | −232.32萬 USD | −172.24萬 USD |
| 淨利 | −831.13萬 USD | −141.16萬 USD | 1.36萬 USD | 378.82萬 USD | 870.4萬 USD |
公司資料更新於 2026年10月11日。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
